Wedoany.com Report-Dec.22, Emcure Pharmaceuticals has commercially launched Poviztra, the second brand of Novo Nordisk's semaglutide injection (known as Wegovy), across India.

The product is supplied in a once-weekly pen device available in five strengths: 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and a maintenance dose of 2.4 mg. Pricing starts at ₹8790 per month for four weekly doses.

Poviztra is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m² or higher (obesity), or 27 kg/m² or higher (overweight) with at least one weight-related health condition such as hypertension, type 2 diabetes mellitus, or dyslipidemia.

It is also approved to reduce the risk of major adverse cardiovascular events—including cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke—in adults with established cardiovascular disease who are living with obesity or overweight.

Satish Mehta, Chief Executive Officer and Managing Director of Emcure Pharmaceuticals, said: "India is facing a significant obesity crisis, having nearly 254 million people living with generalized obesity and an additional 351 million living with abdominal obesity. Through our strong distribution capabilities and pan-India reach, we aim to ensure that more patients can benefit from advanced therapies like semaglutide."

Obesity is associated with more than 230 health complications, including cardiovascular disease, fatty liver, knee osteoarthritis, polycystic ovary syndrome, kidney disease, and Alzheimer's disease. The launch of Poviztra provides an additional treatment option to help address these challenges.

By introducing a locally manufactured semaglutide brand, Emcure aims to improve accessibility for patients across the country. The company's extensive distribution network will support availability in urban and rural areas, enabling broader reach for individuals seeking medically supervised weight management.

The product offers a convenient once-weekly administration, which may improve treatment adherence compared to daily therapies. Healthcare professionals can now prescribe Poviztra for eligible patients as part of a comprehensive approach that combines medication with lifestyle modifications.

This development reflects Emcure's commitment to bringing advanced therapies to Indian patients while addressing the growing burden of obesity-related conditions. The launch is expected to contribute to better disease management and quality of life for those affected.